Introduction: Targeted therapies such as tyrosine kinase inhibitors (TKIs) have dramatically improved the treatment of lung adenocarcinoma, and detection of activating mutations of genes such as EGFR or anaplastic lymphoma kinase gene (ALK) is now mandatory in the clinical setting. However, additional targetable alterations are continuously being described and forcing us to adapt our detection methods. Here we have evaluated the ability of eight amplicon-based next-generation sequencing (NGS) panels to detect the recently described mesenchymal epithelial transition factor (MET) exon 14 (METex14) alterations or new mutations conferring resistance to TKIs.
Introduction
The constant discovery of targetable activating mutations and new-generation tyrosine kinase inhibitors (TKIs) has improved response rates, time to progression, and overall survival in advanced NSCLC. Clinical studies have recently shown that in addition to EGFR-mutated or anaplastic lymphoma kinase gene (ALK)-mutated tumors sensitive to TKIs, tumors with mesenchymal epithelial transition factor (MET) exon 14 (METex14) splicing mutations or mutations altering a direct binding site for c-Cbl at tyrosine 1003 (Tyr1003) could be sensitive to MET inhibitors. 1 Furthermore, mutations conferring acquired resistance to EGFR, ALK, or ROS1 inhibitors are emerging and have to be screened to adjust the treatment of tumors with the corresponding alterations. [2] [3] [4] [5] [6] These new mutations must be detected in diagnostic tests as efficiently as are other well-known targetable mutations, such as EGFR activating mutations. This constantly growing number of essential biomarkers makes it necessary to evolve from single-gene companion tests to next-generation sequencing (NGS). In a clinical context, NGS targeted gene panels represent a good option for rapid, cost-efficient, and samplepreserving cancer genomic profiling to guide therapeutic decisions, but this approach could present some drawbacks that are illustrated here. 7, 8 In this article, we have reported our experience in detecting METex14 mutations by Sanger sequencing with homemade design versus by two commercially available amplicon-based NGS panels. We highlight NGS panel limitations concerning detection of MET mutations, in particular, false-negative cases. We therefore analyze in silico the ability of several other ampliconbased NGS panels to specifically detect METex14 mutations as well as the new resistance mutations of ALK, ROS1, or EGFR. Our results reveal that currently, these panels are not tailored to detect all these recently described mutations. It seems necessary to use additional or alternative solutions to decrease the risk of false-negative results and inappropriate patient selection for targeted therapies in NSCLC.
Materials and Methods

Patients and Samples
On the basis of tumor samples from patients with NSCLC referred to our laboratory for molecular characterization between October 2011 and August 2016, 253 tumors with a tumor content higher than 20% and without EGFR (exons 18 to 21), KRAS (exon 2), or BRAF (codon Val600) activating mutation were screened for METex14 splicing or Tyr1003 mutations.
METex14 Mutation Detection
Sanger sequencing was performed after polymerase chain reaction amplification of two overlapping amplicons, exploring the nucleotides c.2888-65 to c.3003 and c.2939 to c.3028þ45 (NM_000245). This assay is designed to cover more than 95% of METex14-mutated cases described by Frampton et al. 9 (Supplementary Table 1 for DNA analysis designed to explore hotspot mutations useful notably in the lung cancer context. Primer location was used to determine the panels' ability to detect in silico relevant METex14 and ALK, ROS1, or EGFR C797S resistance mutations. METex14 mutations reported only in patients with lung cancer were extracted from Frampton et al. 9 (Supplementary Data), Awad et al., 10 Liu et al., 11 Paik et al., 12 and Tong et al. 13 or identified in our laboratory. Major ALK (NM_004304), ROS1 (NM_002944), and EGFR C797S (NM_005228) resistance mutations were also investigated. [2] [3] [4] [5] [6] Alterations located entirely inside an amplicon (primers excluded) were considered potentially detectable irrespective of their size.
Results
METex14 Detection by Sanger Sequencing
A total of 253 samples from 250 patients with NSCLC (190 men and 60 women) were tested for METex14 mutations. The median age of the patients was 62 years (range 25-97). The cohort of 253 samples was composed of 191 samples from patients with adenocarcinoma, 24 from patients with squamous cell carcinoma, and 38 from patients with NSCLC not otherwise specified. Sanger sequencing was interpretable for 246 of 253 samples. METex14 alterations were identified in five patients (2%) listed in Table 1 . Identical or similar mutations were previously reported in the literature. As described in other studies, patients presenting METex14 mutation tended to be older, 10, 13, 14 even if our positive cohort was too small to allow statistical analysis.
METex14 Mutation Detection by Targeted NGS
Two amplicon-based NGS panels were implemented in our laboratory for routine clinical diagnosis of other targetable mutations such as EGFR (activating mutations of exons 18-21 and resistance mutation T790M), KRAS, and BRAF mutations in 2016. We thus considered the possibility of using these panels to also identify METex14 alterations. Because the five positive METex14 samples were received before implementation of the NGS, we retrospectively analyzed them with our panels. However, the target region visualization shows that neither panel was able to simultaneously detect all five mutations identified by Sanger sequencing (Fig. 1) . In addition, as summarized in Table 1 , only three mutations could be correctly detected by NGS. One mutation could not be confirmed on account of insufficient quality of the DNA, and the last one was not detected. Although located in the TS26 target region, the c.2990_3019del NGS false-negative case can be explained by the location of the deletion in the primer binding site of the two adjacent amplicons covering METex14 ( Fig. 2A and B) .
In silico Comparison of Commercially Available Targeted NGS Panels
To be more comprehensive, we extended our comparison to six additional commercially available panels dedicated to cancer mutation detection on DNA and based on amplicon technology. The ability of these eight panels to detect METex14 and other recently described and clinically relevant alteration, such as ALK, ROS1, and EGFR C797S resistance mutations, was tested in silico by using primer location, as described in the Materials and Methods.
Concerning detection of METex14 alterations, 275 mutated samples (270 extracted from the literature and five identified in this work) corresponding to 151 distinct mutations were listed. These samples were classified into three categories according to the location and/or the size of the alteration: mutations altering the splice acceptor site and/or the splice branch site (AS/ Branch site), mutations altering the splice donor site and/or Tyr1003 codon (DS/Y1003) and large deletions (>150 base pairs) (Supplementary Table 1 ). The ability of the different panels to detect the three classes of METex14 mutations is summarized in Table 2 . Only three panels were able to detect DS/Y1003 mutations, but they were insufficient to detect mutations altering the AS/branch site. Conversely, the three panels detecting the most AS/branch site mutations were unable to detect the DS/Y1003 mutations. In addition, the amplicon-based technology does not allow the detection of large deletions. Finally, none of the panels would have been able to detect more than 63% of the reported cases of METex14 mutations, and most of them would have detected less than 24% of the expected cases. Concerning the detection of ALK mutations involved in TKI resistance, only two panels were able to detect all the major hotspots (Table 3) , and only five of them could detect the crucial gatekeeper p.1196 position. It may be noted that one panel was not designed to explore either METex14 or ALK mutations of interest. Among other new druggable alterations, the EGFR C797S mutation was virtually detectable with six of eight panels. However, (1); amplification of mutated DNA failed, a phenomenon call allele drop-out. For the second amplicon, primer hybridization was possible because only the last nucleotides of the primer were located under the deletion. Wild-type (2) and mutated (3) DNA were amplified, but because of data processing and notably primer trimming, the deletion was removed (3) and its presence can only be suspected owing to the low depth of sequencing (4).
none of these panels was intended to study the ROS1 gene, so ROS1 resistance mutations such as G2032R and D2033N could not be detected (data not shown).
Discussion
NGS technology has emerged as a major tool for diagnosis, prognosis, and detection of clinically druggable genetic alterations in cancer specimens. The challenge is to choose adapted technologies to analyze, with confidence, the most useful genomic regions with low-quantity and poor-quality formalin-fixed paraffin-embedded DNA in a short time. These constraints have justified the use of restrained amplicon-based NGS approaches, 8 but they require continuous reevaluation of genomic regions of interest and have now reached limitations justifying taking an interest in other analysis strategies. 7 This has been illustrated here in particular for the detection of METex14 mutations. Because of major limitations of the commercial panels we use routinely and the false-negative result, we explored in silico the adequacy of other commercially available ampliconbased NGS panels for the detection of these mutations. Similar limitations were observed with all these additional panels and also for other recently described druggable alterations such as ALK, ROS1, and EGFR C797S resistance mutations. However, these alterations and their clinical relevance were less documented at the time of panel design. Thus, no particular optimization was done to cover them efficiently. Updating an existing panel is time-consuming and expensive; consequently, commercially available NGS panels could be rapidly outdated as new regions to be covered emerge frequently. Now, new panels based on nonamplicon technology or combining DNA and RNA sequencinq are available for the study of formalin-fixed paraffin-embedded samples. They are more adapted to detection of the alteration described here, and especially to the detection of various fusions genes or exons skipping druggable in the NSCLC context. Pending the diagnostic validation and routine use of such panels, complementary technologies should be implemented to minimize loss of information. In our laboratory, we have maintained METex14 Sanger sequencing concomitantly with NGS analysis, and this recently allowed us to identify a second false-negative case (c.2888-32_2888-9 del) in a patient with NSCLC not otherwise specified with some sarcomatoid features (biopsy sample) that was undetectable with any of the panels discussed in this report.
Here we have highlighted the crucial role of the best knowledge of panels used in routine diagnosis for accurate identification of gene alterations regardless of the technology selected. Information about the exact genomic regions covered and primer positions have to be carefully checked. Frequent reevaluation should be done to remain up-to-date. This is mandatory to deliver the most accurate data to the clinician for therapeutic decisions.
